Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ranger DCB
- Development stage
- Unknown
- Lead developer
- Boston Scientific
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Intra-arterial, Percutaneous
01
Overview
Ranger DCB (Drug-Coated Balloon) is a medical device-drug combination developed by Boston Scientific for the treatment of peripheral artery disease (PAD), specifically targeting lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA). The device consists of a balloon catheter coated with a proprietary TransPax formulation, which utilizes a citrate ester excipient to deliver a low-dose density (2 μg/mm²) of the anti-proliferative drug paclitaxel. During percutaneous transluminal angioplasty (PTA), the balloon is inflated against the arterial wall, facilitating the local transfer of paclitaxel. Paclitaxel acts by stabilizing microtubules, thereby inhibiting the migration and proliferation of smooth muscle cells that lead to neointimal hyperplasia and restenosis. Ranger DCB received CE Mark in 2014 and FDA approval in November 2020, supported by clinical data from the RANGER II SFA and COMPARE randomized controlled trials.
- Brand names
- RangerRanger DCB
- Other names
- Ranger Drug-Coated BalloonRanger Paclitaxel-Coated PTA Balloon Catheter
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Ranger DCB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ranger DCB.